Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity

Journal of Bone and Mineral Research

Volumn 19, Issue 4, 2004, Pages 623-629

  Sato, Masahiko ^a   Westmore, Michael ^a   Ma, Yanfei L ^a   Schmidt, Allen ^a   Zeng, Qing Q ^a   Glass, Emmett V ^b   Vahle, John ^a   Brommage, Robert ^c   Jerome, Christopher P ^d   Turner, Charles H ^e  

^a ELI LILLY AND COMPANY   (United States)

^b MedFocus   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d SkeleTech Inc   (United States)

^e INDIANA UNIVERSITY   (United States)

Author keywords

CT; Biomechanics; Bone histomorphometry; Parathyroid hormone; Proximal femora; Recombinant human parathyroid hormone (1 34)

Indexed keywords

PARATHYROID HORMONE[1-34]; RECOMBINANT PROTEIN;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MARROW; BONE MASS; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CELL COMPOSITION; CELL COUNT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DOSE RESPONSE; DRUG EFFECT; EXCISION; FEMUR; FEMUR NECK; HIP; LIPID METABOLISM; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; OVARIECTOMY; POROSITY; PRIMATE; QUANTITATIVE ANALYSIS; THICKNESS; TRABECULAR BONE; VOLUMETRY; ANIMAL; FEMALE; MACACA; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOGRAPHY; TENSILE STRENGTH;

ANIMALS; BONE DENSITY; FEMALE; FEMUR NECK; MACACA FASCICULARIS; OSTEOPOROSIS; OVARIECTOMY; POROSITY; RECOMBINANT PROTEINS; TENSILE STRENGTH; TERIPARATIDE;

EID: 6344261898     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040112     Document Type: Article

References (29)

1. Hock JM 2001 Anabolic actions of PTH in the skeletons of animals. J Musculoskel Neuron Interact 2:33-47.
2. Rubin MR, Cosman F, Lindsay R, Bilezikian JP 2002 The anabolic effects of parathyroid hormone. Osteoporos Int 13:267-277.
3. Cosman F, Lindsay R 1998 Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int 62:475-480.
4. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555.
5. Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, Brommage R, Turner CH 2000 Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 11:871-880.
6. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
7. Bagi CM, Wilkie D, Georgelos K, Williams D, Bertolini D 1997 Morphological and structural characteristics of the proximal femur in human and rat. Bone 21:261-267.
8. Turner CH, Burr DB 1993 Basic biomechanical measurements of bone: A tutorial. Bone 14:595-608.
9. Hesp R, Hulme P, Williams D, Reeve J 1981 The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1-34). Metab Bone Dis Relat Res 2:331-334.
10. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM 2001 Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157-165.
11. Turner CH 2002 Biomechanics of bone: Determinants of skeletal fragility and bone quality. Osteoporos Int 13:97-104.
12. Jerome CP, Peterson PE 2001 Nonhuman primate models in skeletal research. Bone 29:1-6.
13. Brommage R, Hotchkiss CE, Lees CJ, Stancill MW, Hock JM, Jerome CP 1999 Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 84: 3757-3763.
14. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R 2001 Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150-159.
15. Uusi-Rasi K, Beck TJ, Oreskovic TL, Sato M, Bogado CE, Zanchetta JR 2002 Teripratide [rhPTH(1-34)] improves the structural geometry of the hip. J Bone Miner Res 17:S1;S208.
16. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL 2003 Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539-543.
17. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480.
18. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694.
19. Boivin GY, Meunier PJ 2002 Effects of bisphosphonates on matrix mineralization. J Musculoskel Neuron Interact 2:538-543.
20. Currey JD 1969 Mechanical consequences of varying the mineral content of bone. J Biomech 2:1-11.
21. Paschalis EP, Burr DB, Mendelsohn R, Hock JM, Boskey AL 2003 Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH(1-34) for 18 months. J Bone Miner Res 18:769-775.
22. Jerome CP, Johnson CS, Vafai HT, Kaplan KC, Bailey J, Capwell B, Fraser F, Hansen L, Ramsay H, Shadoan M, Lees CJ, Thomsen JS, Mosekilde L 1999 Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 25:301-309.
23. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853.
24. Jiang Y, Zhao J, Eriksen EF, Wang O, Genant HK, Mitlak BH 2002 Improved 3D microstructure of cancellous and cortical bone in a multicenter, double-blind, randomized and placebo controlled study of teriparatide (rhPTH(1-34)). J Bone Miner Res 17:S1;S135.
25. Dempster DW 2002 The impact of bone turnover and bone-active agents on bone quality: Focus on the hip. Osteoporos Int 13:349-352.
26. Hirano T, Burr DB, Cain RL, Hock JM 2000 Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). Calcif Tissue Int 66:456-460.
27. Mashiba T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM 2001 Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 28:538-547.
28. Ishizuya T, Uzawa T, Takao R, Hori M, Yamaguchi A 1991 Parathyroid hormone inhibits differentiation of bone marrow adipocytes. J Bone Miner Res 14:S1;S209.
29. Ma L, Westmore M, Turner CH, Hock J, Vahle J, Sato M 2001 Dramatic skeletal effects of PTH in male and osteopenic ovariectomized rats after 1 year of subcutaneous administration. J Bone Miner Res 16:S1;S292.